Which has stronger earnings and valuation, COGT or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A Ascentage Pharma Group International $82.10M 19.28 -$177.71M N/A N/A

Is COGT or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% Ascentage Pharma Group International N/A N/A N/A

Which has higher valuation & earnings, MIRM or AAPG?

Mirum Pharmaceuticals has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $521.31M 12.22 -$23.36M -$14.55 N/A Ascentage Pharma Group International $82.10M 19.28 -$177.71M N/A N/A

Which has stronger earnings & valuation, AAPG or TVTX?

Travere Therapeutics has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.28 -$177.71M N/A N/A Travere Therapeutics $490.73M 12.87 -$25.55M -$0.46 N/A

Which has stronger earnings and valuation, AAPG or KNSA?

Kiniksa Pharmaceuticals International has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.28 -$177.71M N/A N/A Kiniksa Pharmaceuticals International $677.56M 9.23 $59.01M $0.97 82.68

Which has higher valuation and earnings, AAPG or ERAS?

Erasca has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 19.28 -$177.71M N/A N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is AAPG or ERAS more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Erasca N/A -38.43% -32.05%

Does the media favor AAPG or ERAS?

In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Erasca. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 10 mentions for Erasca. Erasca's average media sentiment score of 1.04 beat Ascentage Pharma Group International's score of 0.25 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ascentage Pharma Group International (AAPG) Competitors

$16.95 +0.24 (+1.44%)

Closing price 03:58 PM Eastern

Extended Trading

$17.11 +0.16 (+0.97%)

As of 04:10 PM Eastern

Compare

AAPG vs. COGT, MIRM, TVTX, KNSA, and ERAS

Should you buy Ascentage Pharma Group International stock or one of its competitors? Ascentage Pharma Group International's main competitors and comparable companies include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), Kiniksa Pharmaceuticals International (KNSA), and Erasca (ERAS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Cogent Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

In the previous week, Cogent Biosciences had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 19 mentions for Cogent Biosciences and 12 mentions for Ascentage Pharma Group International. Cogent Biosciences' average media sentiment score of 0.87 beat Ascentage Pharma Group International's score of 0.25 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Ascentage Pharma Group International	N/A	N/A	N/A

Cogent Biosciences currently has a consensus target price of $49.40, suggesting a potential upside of 34.24%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 173.91%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Ascentage Pharma Group International	$82.10M	19.28	-$177.71M	N/A	N/A

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 6 of the 9 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Ascentage Pharma Group International has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Ascentage Pharma Group International's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Ascentage Pharma Group International	N/A	N/A	N/A

Mirum Pharmaceuticals has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.22	-$23.36M	-$14.55	N/A
Ascentage Pharma Group International	$82.10M	19.28	-$177.71M	N/A	N/A

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 10 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.29 beat Ascentage Pharma Group International's score of 0.25 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals presently has a consensus price target of $137.33, indicating a potential upside of 40.02%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 173.91%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Summary

Ascentage Pharma Group International beats Mirum Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Travere Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Travere Therapeutics has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.28	-$177.71M	N/A	N/A
Travere Therapeutics	$490.73M	12.87	-$25.55M	-$0.46	N/A

Ascentage Pharma Group International has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Ascentage Pharma Group International's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Ascentage Pharma Group International presently has a consensus price target of $46.43, suggesting a potential upside of 173.91%. Travere Therapeutics has a consensus price target of $61.67, suggesting a potential downside of 7.97%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 9 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.10 beat Ascentage Pharma Group International's score of 0.25 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascentage Pharma Group International beats Travere Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Kiniksa Pharmaceuticals International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Ascentage Pharma Group International's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Ascentage Pharma Group International presently has a consensus target price of $46.43, suggesting a potential upside of 173.91%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 8.95%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts clearly believe Ascentage Pharma Group International is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kiniksa Pharmaceuticals International has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.28	-$177.71M	N/A	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.23	$59.01M	$0.97	82.68

Ascentage Pharma Group International has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 10 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.63 beat Ascentage Pharma Group International's score of 0.25 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Kiniksa Pharmaceuticals International beats Ascentage Pharma Group International on 8 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Erasca?

Ascentage Pharma Group International (NASDAQ:AAPG) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Ascentage Pharma Group International's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Erasca	N/A	-38.43%	-32.05%

Ascentage Pharma Group International currently has a consensus price target of $46.43, suggesting a potential upside of 173.91%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 24.39%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Erasca has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	19.28	-$177.71M	N/A	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Erasca. MarketBeat recorded 12 mentions for Ascentage Pharma Group International and 10 mentions for Erasca. Erasca's average media sentiment score of 1.04 beat Ascentage Pharma Group International's score of 0.25 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Summary

Ascentage Pharma Group International beats Erasca on 7 of the 12 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.56B	$4.04B	$7.31B	$12.78B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	N/A	11.87	271.78	24.18
Price / Sales	19.28	1,430.05	696.74	129.13
Price / Cash	N/A	44.27	28.87	36.86
Price / Book	19.04	17.49	11.34	6.52
Net Income	-$177.71M	-$22.76M	$3.46B	$347.97M
7 Day Performance	-6.20%	4.71%	3.23%	1.57%
1 Month Performance	-7.33%	12.26%	8.82%	5.24%
1 Year Performance	-61.02%	60.84%	27.70%	17.87%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	3.9805 of 5 stars	$16.95 +1.4%	$46.43 +173.9%	-65.1%	$1.56B	$82.10M	N/A	600	Earnings Report
COGT Cogent Biosciences	2.9761 of 5 stars	$37.00 +4.8%	$49.40 +33.5%	+198.9%	$6.42B	N/A	N/A	80	Positive News Analyst Upgrade
MIRM Mirum Pharmaceuticals	3.5976 of 5 stars	$96.49 -0.6%	$137.33 +42.3%	+35.2%	$6.27B	$618.07M	N/A	140	Positive News
TVTX Travere Therapeutics	1.6764 of 5 stars	$66.08 +2.5%	$61.67 -6.7%	+264.0%	$6.23B	$591.33M	N/A	460	Positive News
KNSA Kiniksa Pharmaceuticals International	3.863 of 5 stars	$79.30 +1.1%	$87.38 +10.2%	+135.2%	$6.19B	$840.85M	81.75	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. COGT, MIRM, TVTX, KNSA, and ERAS

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Summary

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Summary

How does Ascentage Pharma Group International compare to Travere Therapeutics?

Summary

How does Ascentage Pharma Group International compare to Kiniksa Pharmaceuticals International?

Summary

How does Ascentage Pharma Group International compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. COGT, MIRM, TVTX, KNSA, and ERAS

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Which has more volatility & risk, COGT or AAPG?

Does the media refer more to COGT or AAPG?

Is COGT or AAPG more profitable?

Do analysts rate COGT or AAPG?

Which has stronger earnings and valuation, COGT or AAPG?

Summary

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Is MIRM or AAPG more profitable?

Which has higher valuation & earnings, MIRM or AAPG?

Which has more risk & volatility, MIRM or AAPG?

Does the media favor MIRM or AAPG?

Do analysts recommend MIRM or AAPG?

Summary

How does Ascentage Pharma Group International compare to Travere Therapeutics?

Which has stronger earnings & valuation, AAPG or TVTX?

Is AAPG or TVTX more profitable?

Do analysts rate AAPG or TVTX?

Which has more volatility & risk, AAPG or TVTX?

Does the media prefer AAPG or TVTX?

Summary

How does Ascentage Pharma Group International compare to Kiniksa Pharmaceuticals International?

Do insiders & institutionals hold more shares of AAPG or KNSA?

Is AAPG or KNSA more profitable?

Do analysts prefer AAPG or KNSA?

Which has stronger earnings and valuation, AAPG or KNSA?

Which has more volatility & risk, AAPG or KNSA?

Does the media favor AAPG or KNSA?

Summary

How does Ascentage Pharma Group International compare to Erasca?

Is AAPG or ERAS more profitable?

Do analysts prefer AAPG or ERAS?

Do insiders and institutionals hold more shares of AAPG or ERAS?

Which has higher valuation and earnings, AAPG or ERAS?

Does the media favor AAPG or ERAS?

Which has more volatility and risk, AAPG or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools